Skip to content
Screener

Bausch Health Companies BHC International — Revenue

Other segment segments

Bausch + Lomb
$1.24B+9.4%
Salix
$639M+17.9%
Diversified
$185M-9.8%
Solta Medical
$171M+51.3%

Similar metrics at other companies

AECOM logo
ACMInternational — Revenue
$889.6M+1.7%
MH
MHInternational — Revenue
$40.82M-5.1%
Titan Machinery logo
TITNInternational — Revenue
$60.44M-35.6%
Hain Celestial Group logo
HAINInternational — Revenue
$166.86M-0.6%
MSA
MSAInternational — Revenue
$138.39M+8.0%
Angi Inc. logo
ANGIInternational — Revenue
$35.65M+6.9%

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$2.21B+3.8%
Enterprise value$21.66B-2.1%
P/S0.2×0.0×

Profitability

See full
Gross margin71.4%
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%
Debt / equity45.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Bausch Health Companies’s 10-Q, filed April 30, 2026.

Filed
Apr 29, 2026, 6:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885590-26-000053
(in millions)Three Months Ended March 31, / Salix / 2026Three Months Ended March 31, / Salix / 2025Three Months Ended March 31, / International / 2026Three Months Ended March 31, / International / 2025Three Months Ended March 31, / Solta Medical / 2026Three Months Ended March 31, / Solta Medical / 2025Three Months Ended March 31, / Diversified / 2026Three Months Ended March 31, / Diversified / 2025Three Months Ended March 31, / Bausch + Lomb / 2026Three Months Ended March 31, / Bausch + Lomb / 2025Three Months Ended March 31, / Total / 2026Total / 2025
Revenues$639$542$285$262$171$113$185$205$1,244$1,137$2,524$2,259
Less:
Cost of goods sold (a)474311210253272730482481
Cost of other revenues161711
Selling, general and administrative105111635235284345439447
Research and development19176685334528
Segment profit$468$371$88$85$75$53$112$127$277$180$1,020$816
Corporate(258)(268)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch Health Companies's international — revenue?
Bausch Health Companies (BHC) reported international — revenue of $285M in Q1 2026.
How has Bausch Health Companies's international — revenue changed year-over-year?
Bausch Health Companies's international — revenue increased by 8.8% year-over-year, from $262M to $285M.
What is the long-term trend for Bausch Health Companies's international — revenue?
Over 4 years (2021 to 2025), Bausch Health Companies's international — revenue has grown at a -0.7% compound annual growth rate (CAGR), from $1.17B to $1.13B.
What does international — revenue mean?
The total gross revenue generated from the sale of pharmaceutical products and services within the international business segment. This metric represents the top-line performance of the company's global operations outside of primary domestic markets. It is a key indicator of market demand and the effectiveness of the international commercial strategy.

Ask your AI about Bausch Health Companies's international — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude